Key takeaways Compounded tirzepatide is a non-FDA-approved preparation made by a pharmacy; it is not the same as the FDA-approved branded products Zepbound and Mounjaro, and the FDA does not review compounded drugs for safety, quality, or effectiveness before they are sold. The legal landscape changed in 2024–2025: the FDA removed tirzepatide from its drug-shortage […]
Key takeaways Fatigue (tiredness) is listed among adverse reactions reported in at least 5% of patients in the Zepbound (tirzepatide) FDA prescribing information; it is not in the at-least-5% list on the Mounjaro label. Plausible, hedged contributors to tiredness include a sharply reduced calorie intake, dehydration from gastrointestinal side effects, and low blood sugar when […]
Key takeaways In the 72-week SURMOUNT-1 trial, adults taking tirzepatide alongside a reduced-calorie diet and increased physical activity lost an average of about 15.0%, 19.5%, and 20.9% of body weight at the 5, 10, and 15 mg weekly doses, versus about 3.1% on placebo. These are trial averages from one specific population, not promises; individual […]
Key takeaways Per the FDA-approved tirzepatide labels (Zepbound and Mounjaro), the medication is a once-weekly subcutaneous injection given in one of three sites: the abdomen, the thigh, or the back of the upper arm. You may self-inject the abdomen or thigh; the back of the upper arm is reserved for when another person gives the […]
Key takeaways In the STEP 1 trial of semaglutide 2.4 mg, weight loss was observed from the first post-randomization measurement at week 4 onward, used with a reduced-calorie diet and increased physical activity. Because semaglutide has a terminal half-life of about one week and the dose is titrated up over roughly four months, meaningful changes […]
Key takeaways Per the FDA-approved Wegovy and Ozempic (semaglutide) labels, semaglutide injection sites are the abdomen, the front of the thigh, or the back of the upper arm, given subcutaneously. The Wegovy label states the injection site (and time of day) can be changed without a dosage modification, but you should always follow the product’s […]
Key takeaways The semaglutide dosing chart differs by product: per its FDA label, Wegovy (chronic weight management) steps up 0.25 → 0.5 → 1 → 1.7 → 2.4 mg once weekly, while Ozempic (type 2 diabetes) steps 0.25 → 0.5 → 1 → 2 mg once weekly. On both labels the 0.25 mg dose is […]
Key takeaways The FDA-approved semaglutide products (Wegovy and Ozempic) are given as a once-weekly subcutaneous injection in the abdomen, thigh, or upper arm, and the site can be changed without a dosage modification. This is general education, not medical advice. Always follow your specific product’s Instructions for Use (IFU) and your prescriber or pharmacist; never […]
Key takeaways For most people, the common gastrointestinal (GI) side effects of semaglutide are mild-to-moderate, non-serious, and tend to ease over days to weeks as the body adjusts. In a pooled analysis of STEP 1-3 participants on semaglutide 2.4 mg, median per-episode durations were about 8 days for nausea, 2 days for vomiting, 3 days […]
Key takeaways The thyroid C-cell tumor warning on FDA-approved tirzepatide (Mounjaro and Zepbound) comes from rat studies; the labels state plainly that it is unknown whether tirzepatide causes these tumors in humans. A personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 is an absolute contraindication — disclose this to your provider […]
